Experienced in Palmoplantar Keratoderma

Claire I. Daien

CHU De Montpellier
Montpellier, FR 
Experienced in Palmoplantar Keratoderma
CHU De Montpellier
Montpellier, FR 
OverviewLocationsClinical Research

Overview

Claire Daien practices in Montpellier, France. Ms. Daien is rated as an Experienced expert by MediFind in the treatment of Palmoplantar Keratoderma. Her top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Necrosis, and Psoriatic Arthritis.

Her clinical research consists of co-authoring 71 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Palmoplantar Keratoderma.

Gender
Female

Locations

CHU de Montpellier
Montpellier, 34000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T
Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Device
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
Can the Peritoneal Cavity be a Source of Regulatory B Cells to Treat Auto-immune Disease?
Can the Peritoneal Cavity be a Source of Regulatory B Cells to Treat Auto-immune Disease?
Enrollment Status: Terminated
Publish Date: June 13, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 3 Less Clinical Trials

71 Total Publications

French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases.
French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases.
Journal: Joint bone spine
Published: May 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Daien's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile